Drug ID:Drug138
Drug Name:GB004
CID:52912218
DrugBank ID:NULL
Modality:Small Molecule
Groups:NULL
US Approved:NULL
Other Approved:NULL
Identifier: NCT03860896, , NCT04556383
Molecular Formula:C22H28ClN3O4
Molecular Weight:433.9 g/mol
Isomeric SMILES:CC(C)(C)OC(=O)N1CCN(CC1)CC2=C(C(=O)N(C=C2)CC3=CC=C(C=C3)Cl)O
Synonyms:Izilendustat; 1303512-02-8; tert-butyl 4-((1-(4-chlorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate; Izilendustat [INN]; 2KL3NSB2NP; tert-butyl 4-[[1-[(4-chlorophenyl)methyl]-3-hydroxy-2-oxopyridin-4-yl]methyl]piperazine-1-carboxylate; 1-Piperazinecarboxylic acid, 4-((1-((4-chlorophenyl)methyl)-1,2-dihydro-3-hydroxy-2-oxo-4-pyridinyl)methyl)-, 1,1-dimethylethyl ester; MFCD32876908; UNII-2KL3NSB2NP; SCHEMBL1770480
Phase 0: 0
Phase 1: 0
Phase 2: 0
Phase 3: 0
Phase 4: 0
Description:NULL

Molecular Structure

2D Molecular Structure

Knowledge Graph

dtIDCIDCompound NameGene IDGene NameSpeciesPubMed IDsAction
dt1102 52912218 Izilendustat 54583 EGLN1 Homo sapiens (human) Inhibitor

  • No data available

Phase Distribution
Phase Description
  • Phase 0: Exploratory trials to assess drug behavior in humans
  • Phase 1: Safety trials to determine safe dosage range
  • Phase 2: Efficacy trials to evaluate therapeutic effects
  • Phase 3: Large-scale trials to confirm efficacy and safety
  • Phase 4: Post-marketing surveillance for long-term safety and efficacy

Trial IDTitlePhaseStatusSponsorIndicationsInterventions
NCT04556383 A Study With GB004 in Adult Subjects With Active Ulcerative Colitis (UC) PHASE2 TERMINATED GB004, Inc. Ulcerative Colitis DRUG: GB004|DRUG: Placebo Details
NCT03860896 GB004 in Adult Subjects With Active Ulcerative Colitis PHASE1 COMPLETED GB004, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. Ulcerative Colitis DRUG: GB004|DRUG: Placebo|DRUG: GB004 Details
NCT05707429 Sexual Function and Quality of Life Among Patients Suffering From Inflammatory Bowel Disease(Inactive Stage) NULL COMPLETED Assiut University Sexual Function Disturbances|Inflammatory Bowel D… OTHER: The Arabic version of The International In… Details
NCT05706038 Impact of Adalimumab Withdrawal or Continuation on Severity of COVID-19 and Risk of IMID Relapse NULL COMPLETED IRCCS San Raffaele Inflammatory Bowel Diseases|Rheumatic Disorder DRUG: Adalimumab Details
NCT05687474 Baby Detect : Genomic Newborn Screening NULL COMPLETED Centre Hospitalier Universitaire de Liege Congenital Adrenal Hyperplasia|Familial Hyperinsu… None Details
NCT05668104 Jing Si Herbal Tea for Long-Coronavirus Disease(COVID) Gut-brain Interaction NA COMPLETED Buddhist Tzu Chi General Hospital Healthy Subjects|COVID-19 Pneumonia|Irritable Bow… DIETARY_SUPPLEMENT: Jing Si Herbal Tea Liquid Pac… Details
NCT05643534 Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years PHASE3 RECRUITING Ardelyx Irritable Bowel Syndrome With Constipation (IBS-C) DRUG: Tenapanor 50 MG|DRUG: Tenapanor 25 mg bid|D… Details
NCT05626023 A Study of Human TH-SC01 Cell Injection for Treating Perianal Fistulas in Patients With Crohn's Disease PHASE1|PHASE2 COMPLETED Jiangsu Topcel-KH Pharmaceutical Co., Ltd. Perianal Fistula|Crohn's Disease DRUG: Human TH-SC01 cell injection Details
NCT05588843 Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis PHASE2 ACTIVE_NOT_RECRUITING Sanofi Colitis Ulcerative DRUG: SAR443122|DRUG: Placebo Details
NCT05584735 Determining the Relationship Between Gut Microbiota and Immune Response to Influenza or COVID-19 Vaccine NULL COMPLETED University of Wisconsin, Madison Inflammatory Bowel Diseases BIOLOGICAL: Influenza vaccine|BIOLOGICAL: COVID-1… Details
NCT05573685 Basket Study (CT-100-002) to Evaluate the Effects of a DiNaMo™ Component Training NA COMPLETED Click Therapeutics, Inc. Rheumatoid Arthritis|Diabetic Neuropathy|Fibromya… DEVICE: DiNaMo Study App|DEVICE: Placebo App Details
NCT05542355 EXL01 in the Maintenance of Steroid-induced Clinical Response/Remission in Participants With Mild to Moderate Crohn's Disease PHASE1 TERMINATED Exeliom Biosciences Crohn Disease DRUG: EXL01|DRUG: Placebo|OTHER: SoC corticostero… Details
NCT05536440 A Study to Learn About Study Medicine Called PF-07261271 in Healthy People PHASE1 COMPLETED Pfizer Healthy DRUG: PF-07261271|DRUG: Placebo Details
NCT05528510 A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis PHASE3 ACTIVE_NOT_RECRUITING Janssen Research & Development, LLC Colitis, Ulcerative DRUG: Guselkumab Dose 1|DRUG: Guselkumab Dose 2|D… Details
NCT07161297 Remimazolam for Colonoscopy in IBD Patients PHASE4 NOT_YET_RECRUITING Humanitas Clinical and Research Center IBD (Inflammatory Bowel Disease) DRUG: Intravenous remimazolam (5 mg initially, wi… Details
NCT05507931 Broccoli Sprouts for Mild Ulcerative Colitis NA COMPLETED University of Michigan Ulcerative Colitis|Ulcerative Colitis Chronic Mild DIETARY_SUPPLEMENT: 1 Serving of broccoli sprouts… Details
NCT05507203 ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 PHASE3 COMPLETED Abivax S.A. Ulcerative Colitis DRUG: ABX464|DRUG: Placebo Details
NCT07156929 Kinetics and Metabolism of Nicotinamide Provided as a Dietary Supplementation NA COMPLETED University Hospital Schleswig-Holstein Respiratory Infection (for Example, Pneumonia, Br… DIETARY_SUPPLEMENT: Controlled-ileocolonic-releas… Details
NCT05466890 Phase 2a to Evaluate PL-8177 in Subjects with Active Ulcerative Colitis (UC) PHASE2 ACTIVE_NOT_RECRUITING Palatin Technologies, Inc Ulcerative Colitis|Ulcerative Colitis Acute|Ulcer… DRUG: PL8177 Placebo|DRUG: PL8177 Details
NCT05389709 A Pharmacy-based Observational Study to Learn More About Iberogast Advance in the Real-world Setting NULL COMPLETED Bayer Functional Gastrointestinal Disorders Such as Irr… DRUG: Iberogast (STW5-II, BAY98-7410) Details

Disease IDDisease NameDefinitionCategoryRelated DrugsMechanism
No data available

Strategy IDTherapeutic StrategySynonymsRelated DrugsMechanism
S04 T-cell homing and retention T-cell trafficking vedolizumab; anti-MAdCAM1 antibodies ; etrolizumab Inhibition of the interaction between α4β7 integrins on T c… Details
S06 Anti-fibrosis fibrosis; tissue remodelling GS-5745; STNM01 Tissue remodelling and destruction in patients with IBD is … Details
S07 Blockade of cytokine Cytokine signalling apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab Various T-cell subsets, their differentiation pathways and … Details

No related literature

You can run management commands to establish drug-literature associations